logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
B

Bin Zhao

xiamen university
H指数:21
被引数:3,714

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Oncogenic driver and therapeutic target: Prolactin signalling axis in retroperitoneal sarcoma

致瘤驱动因子和治疗靶点： retroperitoneal sarcoma 中催乳素信号轴

Clinical and Translational Medicine
IF6.8
2026-05-050
OAAI
Xie, Fu'an; Gu, Lingwei; Yang, Kunrong; Wang, Shuai; Xiao, Mengmeng; Yan, Guangting; Zhang, Quan; Liang, Rubing; Zhuang, Aobo; Xi, Zhe; Niu, Yujia; Chen, Yanhua; Xia, Xiaogang; Qu, Linlin; Zhao, Bin; Li, Weibing; Wu, Ting; Yu, Chundong; Luo, Chenghua; Wang, Houzhao; Lian, Lanlan; Li, Wengang
The Phase 3 KEYLYNK-006 Study of Pembrolizumab Plus Olaparib Versus Pembrolizumab Plus Pemetrexed as Maintenance Therapy for Metastatic Nonsquamous NSCLC

KEYLYNK-006 III期研究：比较培美曲塞联合奥拉帕利与培美曲塞联合培美曲塞作为转移性非鳞状非小细胞肺癌维持治疗的疗效。

JOURNAL OF THORACIC ONCOLOGY
IF20.8
2025-02-013
PRE
Gray, Jhanelle E.; Schenker, Michael; Sendur, Mehmet Ali Nahit; Leonova, Viktoriya; Kowalski, Dariusz; Kato, Terufumi; Orlova, Rashida; Yang, James Chih-Hsin; Langleben, Adrian; Pilz, Arnold; Ungureanu, Andrei; Mak, Milena Perez; De Angelis, Flavia; Aggarwal, Himani; Zimmer, Zachary; Zhao, Bin; Shamoun, Mark; Kim, Tae Min
Pembrolizumab With or Without Maintenance Olaparib for Metastatic Squamous NSCLC That Responded to First-Line Pembrolizumab Plus Chemotherapy

Pembrolizumab联合或不维持Olaparib用于转移性鳞状NSCLC，对一线Pembrolizumab加化疗有反应

JOURNAL OF THORACIC ONCOLOGY
IF20.8
2025-02-011
OAAI
Hochmair, Maximilian; Schenker, Michael; Dols, Manuel Cobo; Kim, Tae Min; Ozyilkan, Ozgur; Smagina, Maria; Leonova, Viktoriya; Kato, Terufumi; Fedenko, Alexander; De Angelis, Flavia; Rittmeyer, Achim; Gray, Jhanelle E.; Greystoke, Alastair; Aggarwal, Himani; Huang, Qinlei; Zhao, Bin; Lara-Guerra, Humberto; Nadal, Ernest
Results from phase 3 KEYLYNK-008: Pembrolizumab (pembro) with and without maintenance olaparib (ola) after first-line (1L) pembro plus chemotherapy (chemo) for metastatic squamous non-small-cell lung cancer (sqNSCLC)
CANCER RESEARCH
IF16.6
2024-04-051
PRE
Hochmair, Maximilian; Schenker, Michael; Dols, Manuel Cobo; Kim, Tae Min; Kim, Sang-We; Ozyilkan, Ozgur; Smagina, Maria; Viktoriya, Leonova; Kato, Terufumi; Fedenko, Alexander; De Angelis, Flavia; Rittmeyer, Achim; Gray, Jhanelle E.; Greystoke, Alastair; Huang, Qinlei; Zhao, Bin; Lara-Guerra, Humberto; Nadal, Ernest
Results from KEYNOTE-B99: Phase 2 study of first-line (1L) pembrolizumab (pembro) plus investigational agents and chemotherapy (chemo) for extensive-stage small-cell lung cancer (ES-SCLC)
CANCER RESEARCH
IF16.6
2024-04-050
PRE
Rodriguez-Abreu, Delvys; Hochmair, Maximillian; Cho, Byoung Chul; Csoszi, Tibor; Kutiel, Talia Shentzer; Mueller, Veronika; Ahn, Myung-Ju; Kowalski, Dariusz; Maio, Michele; Moiseyenko, Vladimir; Navarro, Alejandro; Niu, Jianxin; Fung, Andrea S.; Lips, Carolin; Zhou, Heng; Zhao, Bin; Lara-Guerra, Humberto; Peled, Nir
Results from KEYNOTE-B98: A phase 1b/2 study of pembrolizumab plus investigational agents in patients with anti-PD-(L)1-refractory extensive-stage small-cell lung cancer (ES-SCLC)
CANCER RESEARCH
IF16.6
2024-04-050
PRE
Navarro, Alejandro; Ahn, Myung-Ju; Stevenson, James; Peled, Nir; Kutiel, Talia Shentzer; Huemer, Florian; Kim, Dong-Wan; Casulleras, Maria Jove; Khattak, Adnan; Kowalski, Dariusz; Leighl, Natasha B.; de Marinis, Filippo; Lips, Carolin; Niu, Jiaxin; Huang, Mo; Zhao, Bin; El-Osta, Hazem; Owonikoko, Taofeek

研究方向

暂未获取到该数据
H
Hong Zhao
H 指数:75论文数:491被引数:3.3万
J
Jiaxin Zhao
H 指数:25论文数:119被引数:2,090
T
Terufumi Kato
H 指数:58论文数:521被引数:2.9万
D
Dariusz M. Kowalski
H 指数:43论文数:334被引数:2.7万
H
Humberto Lara-Guerra
H 指数:13论文数:44被引数:1,047
易鸣 封面图
易鸣
H 指数:56论文数:188被引数:1.4万
戴
戴志军
H 指数:53论文数:439被引数:1.0万
M
Myung‐Ju Ahn
H 指数:109论文数:1,300被引数:7.1万
B
Byoung Chul Cho
H 指数:106论文数:1,591被引数:6.9万
T
Tae Min Kim
H 指数:69论文数:757被引数:2.1万